Share This
Hepatitis
Hepatitis (plural hepatitides) implies inflammation of the liver characterized by the presence of inflammatory cells in the tissue of the organ. The name is from ancient Greek hepar (ἧπαρ), the root being hepat- (ἡπατ-), meaning liver, and suffix -itis, meaning "inflammation" (c. 1727). The...
Learn more about Hepatitis »
Add More Topics
Save this view to a base, or just for yourself.
6 Medical Treatment topics matching:
Filter this CollectionRibavirin
Ribavirin (brand names: Copegus, Rebetol, Ribasphere, Vilona and Virazole) is an anti-viral drug indicated for severe RSV infection (individually), hepatitis C infection (used in conjunction with peginterferon alfa-2b or peginterferon alfa-2a) and...
Liver transplantation
Liver transplantation or hepatic transplantation is the replacement of a diseased liver with a healthy liver allograft. The most commonly used technique is orthotopic transplantation, in which the native liver is removed and the donor organ is...
Adefovir
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI).
It is used for treatment of hepatitis B.
It is a failed treatment for HIV....
Entecavir
Entecavir (INN) (pronounced /ɛnˈtɛkəvɪr/) is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a nucleoside analog (more specifically, a guanine analogue) that...
Pegylated interferon-alpha-2b
Pegylated interferon alfa-2b is a treatment for hepatitis C developed by Schering-Plough, brand name is Peg Intron.
It was approved in January 2001.
PEG-interferon alpha is a pegylated interferon composed of 165 amino acids. The PEG (polyethylene...
Used To Treat:
Telbivudine
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be...